Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic to Acquire Biorepository from Gene Logic

NEW YORK (GenomeWeb News) – Transgenomic today said that it has signed an agreement to acquire the biorepository assets of Gene Logic for $250,000 in cash.

The biorepository contains 60,000 human tissue samples and extracted DNA specimens with linked clinical information and will be used to validate Transgenomic's assays. Specifically, Omaha, Neb.-based Transgenomic said that it will use the samples in development and validation of its Reveal family of Ice Cold-PCR-based oncology assays as well as its Wave MCE System and Surveyor Scan Mutation Detection Kits.

"This transaction significantly strengthens Transgenomic's position in translational medicine services, providing a deep source of clinical samples allowing us to validate new drug-associated genetic targets," Transgenomic CEO Craig Tuttle said in a statement. "The biorepository provides not only strategic and operational benefits, but also long-term cost savings."

Gene Logic, a subsidiary of Ocimum Biosolutions, had filed for bankruptcy protection last year, and earlier this year its assets were put up for auction.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.